GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
+2.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 6.7K | 15.0K | 25.6K |
| Gross Profit | — | — | (6.7K) | (15.0K) | (25.6K) |
| Operating Expenses | |||||
| R&D Expense | 9.8M | 9.4M | 10.5M | 17.6M | 11.5M |
| SG&A Expense | 6.0M | 6.1M | 10.6M | 13.4M | 12.3M |
| General & Admin Expense | 6.0M | 6.1M | — | 13.4M | — |
| Selling & Marketing Expense | (3.00) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 15.8M | 15.5M | 21.2M | 31.1M | 23.8M |
| Cost and Expenses | 15.8M | 15.5M | 21.2M | 31.1M | 23.8M |
| Operating Income (EBIT) | (15.8M) | (15.5M) | (21.2M) | (31.1M) | (23.8M) |
| Non-Operating | |||||
| Interest Income | 17.7K | — | 63.6K | 215.1K | 90.1K |
| Interest Expense | 455.5K | 739.9K | — | — | — |
| Net Interest Income | (437.9K) | (739.9K) | 63.6K | 215.1K | 90.1K |
| Other Non-Op Income/Expense | (655.9K) | (713.3K) | 63.0K | 215.1K | 90.1K |
| Non-Operating Income (excl Interest) | (84.1K) | (26.6K) | (63.0K) | (215.1K) | (90.1K) |
| EBT (Pre-Tax Income) | (16.5M) | (16.2M) | (21.1M) | (30.9M) | (23.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (16.5M) | (16.2M) | (21.1M) | (30.9M) | (23.7M) |
| Earnings from Cont. Ops | (16.5M) | (16.2M) | (21.1M) | (30.9M) | (23.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (16.5M) | (16.2M) | (21.4M) | (30.9M) | (23.7M) |
| Per Share | |||||
| Basic EPS | ($158.78) | ($382.80) | ($5,872.98) | ($24,838.00) | ($21,780.00) |
| Diluted EPS | ($158.78) | ($382.80) | ($5,872.98) | ($24,816.00) | ($21,780.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 473162 | 42397 | 3642 | 1243 | 1089 |
| Diluted Shares Outstanding | 473162 | 42397 | 3642 | 1243 | 1090 |
| Profitability Metrics | |||||
| EBITDA | (15.8M) | (15.5M) | (21.1M) | (30.8M) | (23.7M) |
| D&A | — | — | 6.7K | 15.0K | 25.6K |
| EBIT | (15.8M) | (15.5M) | (21.1M) | (30.9M) | (23.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026